Gastro-entero-pancreatic Neuroendocrine Tumors

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2025-01-13
Clinical Trial Update: 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors [Phase 2]
A Phase 2 trial evaluating Lu-177 dotatate–based PRRT with or without capecitabine for FDG-positive gastro-entero-pancreatic neuroendocrine …